A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety.
Li, Y., Liu, J., Chen, W., Wang, W., Yang, F., Liu, X., Sheng, Y., Du, K., He, M., Lyu, X., Li, H., Zhao, L., Wei, Z., Wang, F., Zheng, S., Sui, J.(2023) J Hematol Oncol 16: 2-2
- PubMed: 36650558 
- DOI: https://doi.org/10.1186/s13045-023-01399-4
- Primary Citation of Related Structures:  
7WN8 - PubMed Abstract: 
The antiphagocytic molecule CD47 is overexpressed in a wide variety of cancer cells, and antibodies targeting CD47 for cancer therapies are currently under intensive investigation. However, owing to the ubiquitous expression of CD47 on healthy cells, anti-CD47 therapies often achieve only weak therapeutic benefits and can induce severe side effects. Here, we report the generation of a pH-dependent anti-CD47 antibody (BC31M4) which selectively binds to tumors under the acidic solid tumor microenvironment.
Organizational Affiliation: 
Peking University-Tsinghua University-National Institute of Biological Sciences (PTN) Joint Graduate Program, School of Life Sciences, Peking University, Beijing, China.